Efgartigimod
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
82
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Myasthenia Gravis Crisis
Conditions
Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis
Trial Timeline
Mar 6, 2025 → Dec 31, 2026
NCT ID
NCT06860633About Efgartigimod
Efgartigimod is a approved stage product being developed by Argenx for Myasthenia Gravis Crisis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06860633. Target conditions include Myasthenia Gravis Crisis, Myasthenia Gravis Exacerbations, AChR Myasthenia Gravis.
Hype Score Breakdown
Clinical
30
Activity
20
Company
7
Novelty
10
Community
12
Clinical Trials (10)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04777734 | Pre-clinical | Completed |
| NCT07011589 | Phase 1/2 | Recruiting |
| NCT06860633 | Approved | Recruiting |
| NCT06298565 | Pre-clinical | Recruiting |
| NCT06299748 | Pre-clinical | Recruiting |
| NCT06203457 | Phase 2 | Completed |
| NCT05918978 | Phase 2 | Terminated |
| NCT04274452 | Phase 3 | Withdrawn |
| NCT04225156 | Phase 3 | Completed |
| NCT04188379 | Phase 3 | Completed |
Competing Products
20 competing products in Myasthenia Gravis Crisis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Satralizumab | Chugai Pharmaceutical | Phase 3 | 77 |
| tacrolimus | Astellas Pharma | Phase 3 | 77 |
| Tacrolimus capsule + Placebo | Astellas Pharma | Phase 3 | 77 |
| tacrolimus + placebo | Astellas Pharma | Phase 3 | 77 |
| Ravulizumab | AstraZeneca | Pre-clinical | 23 |
| Cladribine Low Dose + Cladribine High Dose | Merck | Phase 3 | 77 |
| Remibrutinib (Blinded) + Remibrutinib (Open Label) | Novartis | Phase 3 | 77 |
| Placebo + CFZ533 | Novartis | Phase 2 | 52 |
| Iptacopan | Novartis | Phase 3 | 77 |
| mycophenolate mofetil [CellCept] + Placebo | Roche | Phase 3 | 77 |
| mycophenolate mofetil (CellCept) + placebo | Roche | Phase 3 | 77 |
| inebilizumab + IV Placebo | Amgen | Phase 3 | 76 |
| Inebilizumab | Amgen | Phase 2 | 51 |
| Abatacept Injection | Bristol Myers Squibb | Phase 1 | 32 |
| Tolebrutininb + Placebo | Sanofi | Phase 3 | 76 |
| Pozelimab + Cemdisiran + Cemdisiran + Pozelimab | Regeneron Pharmaceuticals | Phase 3 | 76 |
| HIZENTRA ® | CSL | Phase 2 | 51 |
| Subcutaneous immunoglobulins | CSL | Phase 1 | 32 |
| Human normal immunoglobulin G (IgG) | CSL | Phase 3 | 76 |
| zilucoplan (RA101495) | UCB | Phase 3 | 74 |